Antares Pharma to Report Third Quarter 2019 Financial and Operating Results
October 29 2019 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release
its third quarter 2019 financial results and recent operating
progress before the market opens on Tuesday, November 5,
2019. Management will host a webcast and conference call at
8:30 a.m. ET (Eastern Time) on November 5, 2019 to discuss the
results.
Interested parties may participate in the
conference call by dialing 1-888-204-4368 or 1-323-994-2093 and
entering access code 8800570. We encourage interested parties
to dial into the conference call at least 10 minutes prior to the
scheduled start time. A replay of the conference call will be
available from 11:30 a.m. ET on Tuesday, November 5, 2019, through
11:30 a.m. ET on Thursday, December 5, 2019 by dialing
1-888-203-1112 or 1-719-457-0820 and entering the access code
8800570. An archive of the slide presentation will also be
available under the “For Investors” section of the Antares Website
at www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused on the development and commercialization of
self-administered parenteral pharmaceutical products using advanced
drug delivery auto injector technology. The Company has a
portfolio of proprietary and partnered commercial products with
several product candidates in advanced stages of development, as
well as significant strategic alliances with industry leading
pharmaceutical companies including Teva Pharmaceutical Industries,
Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc.
(Pfizer). Antares Pharma’s proprietary products include
XYOSTED™ (testosterone enanthate) injection, OTREXUP®
(methotrexate) injection for subcutaneous use and Sumatriptan
Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: market acceptance,
adequate reimbursement coverage and commercial success of XYOSTED™
and future revenue from the same; market acceptance of Teva’s
generic epinephrine auto-injector product and future revenue from
the same;; future market acceptance and revenue from Makena®
subcutaneous auto injector; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; continued growth of prescriptions and sales
of OTREXUP®; the timing and results of the Company’s or its
partners’ research projects or clinical trials of product
candidates in development including projects with Teva and Pfizer
and our proprietary programs for ATRS-1701 and our
development program for the use of subcutaneous methotrexate for
the treatment of ectopic pregnancy; actions by the FDA or other
regulatory agencies with respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; achievement of the 2019
revised revenue guidance; the Company’s ability to meet loan
extension and interest only payment milestones and the ability to
repay the debt obligation to Hercules Capital; successful
completion of the transaction with Ferring International Center,
S.A.; the Company’s ability to obtain financial and other resources
for its research, development, clinical, and commercial activities
and other statements regarding matters that are not historical
facts, and involve predictions. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contacts:Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024